• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 20, 2020

View Archived Issues
Man having temperature check

COVID-19 challenge study to start in the U.K. next year

LONDON - The world’s first COVID-19 human challenge trial is due to start in London next year, after the government announced £33.6 million (US$42.5 million) funding for the project. In the initial phase, the aim is to establish the dose of SARS-CoV-2 needed to cause infection and to characterize the immune response to virus. That will lead on to tests of individual COVID-19 vaccines, in which volunteers will be challenged with the effective dose of SARS-CoV-2 one month after inoculation. Read More

Redeeming qualities in PTSD phase II – for Aptinyx shares, too

Aptinyx Inc. CEO Norbert Riedel said the design is unclear of the pivotal trial due next year with the N-methyl-D-aspartate (NMDA) receptor modulator NYX-783 in post-traumatic stress disorder (PTSD), as fine points must be hashed out with the FDA. Read More
Merger-arrows-black-white.png

Hello, Cleveland Biolabs! Here comes a merger with Cytocom

Privately held Cytocom Inc. and Cleveland Biolabs Inc. will merge in an all-stock transaction, with Cytocom shareholders taking the majority position. The transaction, which must be approved by Cleveland Biolabs’ shareholders, is expected to close in the first quarter of 2021. Read More
Ocular-digital-eye

Sparingvision adds $52.5M for gene therapy trial, expansion to U.S.

LONDON – Sparingvision SAS has raised €44.5 million (US$52.5 million) to advance SPVNo6, a gene therapy designed to be effective for all retinitis pigmentosa patients regardless of the underlying mutation, with a phase I dose-ranging study now due to start in 2021. Read More
Test-tube-dropper-research

Investors warm to drug developers ahead of catalysts and financial results

Investors appear to be maintaining a bullish outlook on biopharma companies developing innovative medicines, with the BioWorld Drug Developers index currently tracking up over 5% in value so far this month heading into third-quarter earnings season. Read More

Curon and Rhizen ink $149.5 million agreement for tenalisib

HONG KONG – La Chaux-de-Fonds, Switzerland-based Rhizen Pharmaceuticals SA has agreed to license its dual PI3K delta and gamma inhibitor tenalisib (RP-6530) to Shanghai-based Curon Biopharmaceutical Ltd. for as much as $149.5 million, inclusive of an upfront payment of undisclosed value and potential milestone payouts. Read More
Nonprofit stamp

Pandemic sweeping biopharma nonprofit deals and grants

COVID-19 continues to dominate biopharma nonprofit collaborations and grants in 2020, with the pandemic accounting for 85% of projected values reported this year, most of which have posted since the start of July. Read More
Sputnik V vaccine

Sputnik V: Secrecy around phase III trials in Venezuela

CAJICA, Colombia – The Russian vaccine candidate Sputnik V, developed by Moscow’s Gamaleya National Research Institute of Epidemiology and Microbiology to prevent the SARS-CoV-2 virus that causes COVID-19, is undergoing phase III trials in Venezuela under complete secrecy. Read More

Appointments and advancements for Oct. 20, 2020

New hires and promotions in the biopharma industry, including: AM-Pharma, Assembly, Atbtherapeutics, Centogene, Heparegenix, Jubilant, Mereo, Perseus, Replimune, Vaccitech. Read More

Financings for Oct. 20, 2020

Biopharmas raising money in public or private financings, including: Acerus, Bellus, Compass. Read More

In the clinic for Oct. 20, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abpro, Aclaris, Appili, Aptinyx, Bone, Cardiff, Cincor, Cytodyn Evofem, Jazz, Keros, Merck, Neuclone, Neuraptive, Noxxon, Ono, Rafael, TFF, Treadwell, Valneva. Read More

Other news to note for Oct. 20, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acorda, Affimed, Arecor, Atriva, Baudax, Biogen, Cara, Chelation, Citranvi, CNS Pharmaceuticals, Cytovant, Dinona, Gigagen, Havn, Hikma, Immunic, Immunomedics, Incelldx, Intrommune, Kineta, Medigene, Mindset, Nascent, Nevakar, Nkmax, Organicell, Oric, Parexel, Proteonic, Revive, Samsung Biologics, Synairgen, Synspira, Tetra, Tscan, Vifor, Voronoi, Zhaoke. Read More

Regulatory actions for Oct. 20, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amacathera, Asklepios, Astrazeneca, Inventiva, Selecta. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe